Mersana Therapeutics, Inc. — Director's Dealing 2021

Jul 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Mersana Therapeutics, Inc. (MRSN)
CIK: 0001442836
Period of Report: 2021-07-20

Reporting Person: Lowinger Timothy B (Chief Science & Tech. Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-20	Common Stock	M	2227	$6.16	Acquired	77400	Direct
2021-07-20	Common Stock	S	2227	$12.11	Disposed	75173	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-20	Stock Option (right to buy)	$6.16	M	2227	Disposed	2030-01-14	Common Stock (2227)	Direct

Footnotes

F1: Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.85 to $12.24, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3: The option vests in equal quarterly installments over the first four years after the vesting commencement date, January 15, 2020.